6. Conclusion
Our analysis provides valuable insights into the safety profiles of pirfenidone and nintedanib in real-world practice. The findings emphasize the importance of monitoring and managing specific ADRs and highlight the need for continued pharmacovigilance efforts to ensure patient safety in the long-term use of these drugs for IPF treatment.